McKesson Packs Patient Outreach
Patients enrolled in a card program can use MPRS outreach programs for improving persistence and outcomes, such as patient messaging, permission-based marketing, and a 600-seat call center for live assistance to doctors, clinicians, nurses, and pharmacists.
With the planned launch of the Burgopak in the United States, McKesson RxPak will be leveraging the capabilities of McKesson Patient Relationship Solutions (MPRS). The MPRS division aims to improve health outcomes by increasing patient awareness of pharmaceutical therapy options and adherence to prescribed drug regimens.
The Burgopak will enable the integration of a McKesson LoyaltyScript card. Using LoyaltyScript programs, pharmaceutical manufacturers can subsidize an eligible patient’s copay or out-of-pocket cost, and build patient relationships through downstream permission-based patient communications, says Derek Rago, vice president, strategy and marketing, MPRS.
“LoyaltyScript removes many of the obstacles that drive patient nonadherence, and ultimately educates and helps patients initiate and stay on prescription therapy,” says Rago.
“These programs have never before been delivered via such an innovative and unique compliance packaging technology. We have just started announcing the ability to leverage the Burgopak to our customers, and the feedback has been very favorable,” Rago adds.
Return to article:
Package delivery of McKesson LoyaltyScript cards provides manufacturers with a new channel for reaching patients. With the card integrated within the package, a program can mitigate card delivery “leakage” that occurs when cards are delivered by sales reps and doctors, and ultimately increase patient access, he says.
“Another exciting opportunity for our customers is to leverage the design of Burgopak to communicate any cross-promotional pharmaceutical brands or complementary OTC therapies, further extending the benefit to patients and ideally assisting to improve their overall health outcome,” Rago says.
MPRS also offers its TrialScript alternate sampling program, that provides patients a free trial supply of physician-prescribed medication, dispensed at the pharmacy. Brands can use TrialScript to acquire new patients by actively involving them in their therapy. Further, patients are more likely to receive adequate dosing support, as they receive the dosing and administration instructions delivered by the pharmacist and with the trade packaging.
Both programs are administered through pharmacy claim adjudication technologies. Manufacturers are therefore provided with greater insight into patient utilization, reduced likelihood of fraud and abuse, and the ability to measure ROI and the overall program effectiveness. Rago says.
“With both programs we have seen a lift in the propensity for physicians to appropriately prescribe more of the drug and an increase in overall patient adherence,” Rago says. “In one study of a TrialScript program, physicians’ wrote 150,000 more prescriptions (or $15 million) than the previous year. In a similar study, a LoyaltyScript program increased the number of refills by more than 50% over 12 months.”
MPRS’s other assets include a 600-seat dedicated call center, automated outbound communications, and clinical support. A Pharmacy Intervention Program supports pharmacy patient outreach services. The program enables a pharmacist to deliver 5-minute intervention, for identifying and addressing a patient’s barriers to adherence.